Article: ImClone Systems, whose shares Martha Stewart ditched, now flying high.

By Josh Goldstein, The Philadelphia Inquirer Knight Ridder/Tribune Business News

Jul. 16--She should have held.

Two-and-a-half years after Martha Stewart sold her stake in ImClone Systems Inc., netting a profit of nearly $167,000 just before the stock's plunge, the company and its shares have come roaring back. ImClone's lead compound is poised to become a blockbuster in the fight against colon cancer.

The decision to sell has got to be doubly painful for the home-and-garden diva.

Had Stewart held on to her 3,928 shares, the value of her holdings would have grown by $85,000, based on the stock's recent surge. And Stewart, 62, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!